HAVCR2 and lung carcinoma: These T cells appeared to resemble a recently described IL7R-HAVCR2+KRT86+DUSP4+LAYN+ subset, which has been associated with response to anti-PD1 therapy in lung cancer (Clarke et al., 2019).